Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491 · View on ClinicalTrials.gov ↗
Study Summary
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Conditions Studied
Interventions
- BIOLOGICAL XmAb541
Study Locations (16)
California
- City of Hope — Duarte
- Stanford — Palo Alto
- University of California — San Francisco
New York
- Icahn School of Medicine at Mount Sinai — New York
- Montefiore Einstein Comprehensive Cancer Center — The Bronx
Florida
- Moffitt Cancer Center — Tampa
Georgia
- Winship Cancer Institute, Emory University — Atlanta
Illinois
- University of Chicago Medical Center — Chicago
Indiana
- Indian University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis
Michigan
- Karmanos Cancer Institute — Detroit
New Jersey
- The John Theruer Cancer Center at Hackensack University Medical Center — Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2024-04-04 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06276491
The ClinicalTrials.gov registry entry for NCT06276491 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 7 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention — of which XmAb541 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06276491 reports 16 study locations spanning 13 distinct geographic areas — top geographies include California, New York, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06276491 about?
NCT06276491 is a clinical study titled "Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors". The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
What is the current status of trial NCT06276491?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 282 participants. The study started on 2024-04-04. Estimated completion is 2028-12.
What conditions does trial NCT06276491 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06276491?
The interventions under investigation include: XmAb541 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06276491?
This trial is sponsored by Xencor, which has 7 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06276491 being conducted?
This trial has 16 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.